Kogenate FS

antihemophilic factor (recombinant) for the treatment of Hemophilia A

Free Trial| EZ Log| Prescribing Information| En Espanol

Contact Us

Search

Searching for programs and tools to help manage hemophilia treatment?

LINK to Bayer HealthCare Pharmaceuticals, Inc. for learning, insights, and knowledge on the real life issues of patients and caregivers in the hemophilia community.

LINK programs are designed to obtain feedback from patients and caregivers and provide important information in an open forum that allows participants to provide feedback on vital treatment and lifestyle issues. These interactive meetings, facilitated by local Bayer HealthCare Hematology Account Executives, are designed to form an even stronger connection between the needs of the hemophilia community and Bayer HealthCare's ongoing efforts to meet them.

LINK with your local Bayer HealthCare Hematology Account Executive. LINK: Learning, Insights and Knowledge

LINK presentations begin with informational slideshows combined with video demonstrations featuring hemophilia experts. Each program also includes interactive presentations and discussion on the following topics:

  • Exciting new product updates
  • Living Beyond Hemophilia, a new community for young people and mentors
  • New EZ-Log Web-based tracking system

If you are searching for programs and tools to help you in living with hemophilia, LINK with your local Bayer HealthCare Hematology Account Executive for more information on a LINK program near you.

*In accordance with government statutes, patients covered in whole or in part by federal or state healthcare programs cannot participate.

INDICATIONS & USAGE

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION

The most serious adverse reactions are systemic hypersensitivity reactions and the development of hightiter inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.

Prescribing Information | Privacy Policy | Terms of Use | Sitemap

© 2009 Bayer HealthCare Pharmaceuticals, Inc. All rights reserved.
BAYER, the Bayer Cross, and Kogenate FS are registered trademarks of Bayer HealthCare Pharmaceuticals.
BIO-SET is a trademark of Biodome SAS.

Kogenate FS Antihemophilic Factor (Recombinant) with BIO-SET Needleless Reconstitution System

Bayer HealthCare Pharmaceuticals